Loading viewer...
investor_presentation
Format: PDF investor_presentation
OPKO Health investor presentation dated November 2020.
NASDAQ: OPKForward Looking Statements
2 November 2020 |This presentation contains “forward -looking statements,” asthatterm isdefined under thePrivate Securities Litigation Reform Actof1995 (PSLRA), which statements may beidentified by
words such as“expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” “potential,” and other words ofsimilar meaning, including statements
regarding expected financial performance andexpectations regarding themarket forandsales ofourproducts, expectations about COVID -19testing, thedemand fortesting, ourcapacity for
testing andexpected turnaround time, theimpact ofCOVID -19onallofourbusinesses, positively andnegatively, ourability toexpand ourcapacity should there beadditional demand, the
availability ofresources, including labor, equipment andsupplies, tomeet demand fortesting andthepotential impact onusshould these resources beconstrained, whether ourturnaround
time willbeasexpected orourperformance quality decline, ourproduct development efforts andtheexpected benefits ofourproducts, ourestimated revenues andfinancial projections,
including expected Rayaldee and BioReference revenues, whether wewillmaintain profitability orcontinue growth atBioReference, whether prescriptions forRayaldee willstabilize or
increase, expected milestones androyalties from theoutlicense ofourproducts, theoutcome ofourclinical trials andvalidation studies andthatsuch outcomes willsupport marketing approval
orcommercialization, theexpected market penetration andsizeofthemarket forourproducts, ourability tosuccessfully commercialize ourproduct candidates such ashGH-CTP, Factor VII-
CTP, andourrare disease product candidates, whether Rayaldee willraise serum total 25-hydroxyvitamin D(25D)more effectively than anyover-the-counter (OTC) orprescription (Rx)
products currently marketed without theriskofhypercalcemia, ourability todevelop Rayaldee fornew indications including stage 5CKD, andthetimeline fordoing so,whether theclinical data
forhGH-CTP willsupport submission ofaBiologics License Application (BLA), thetiming ofsuch submission, andapproval forhGH-CTP inadults andpediatric patients, whether wewillbe
required tomake anychanges toourdevelopment plans forhGH-CTP andincrease ourexpenditures, expectations regarding patent coverage, theexpected timing forcommencing, enrolling,
completing andannouncing results forourclinical trials, thetiming forrelease oftrialdata andseeking andobtaining FDA andEuropean regulatory approvals aswell asreimbursement
coverage forourproducts .These forward -looking statements areonly predictions and reflect ourviews asofthedate they were made, and weundertake noobligation toupdate such
statements .Such statements aresubject tomany risks anduncertainties thatcould cause ouractivities oractual results todiffer materially from theactivities andresults anticipated inforward
Preview truncated — download the full document for the complete content.
investor_presentation
27 Pages
OPKO Health Investor Presentation — September 2017
investor_presentationinvestor_presentation
23 Pages
OPKO Health Investor Presentation — September 2017
investor_presentationinvestor_presentation
23 Pages
investor_presentation
36 Pages
SES